Efficacy and safety of dulaglutide when used instead of sitagliptin in type 2 diabetic patients

Efficacy and safety of dulaglutide when used instead of sitagliptin in type 2 diabetic patients - Efficacy and safety of dulaglutide when used instead of sitagliptin in type 2 diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023245

Enrollment

Registered

2016-07-25

Start date

2016-07-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

The patients are treated with dulaglutide instead of sitagliptin from the start to the 24th week.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes with HbA1c =/> 6.5%

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes 2. Patients with severe renal failure or liver dysfunction 3. Patients with drug allergy for ipraglifrozin 4. Patients with history of diabetec ketosis 5. Patients with shick day

Design outcomes

Primary

Measure	Time frame
Change of HbA1c,body weight at the 12th and the 24th week.	—

Secondary

Measure	Time frame
Change of data shown below at the 12th and the 24th week. AST, ALT, gamma-GTP, LDL-C, HDL-C,TG, non-HOL-C, serum creatinine, serum UA	—

Countries

Japan

Contacts

Public ContactTomoyuki Iwasaki

Iwasaki Naika Clinic Endocrinology and Metabolism

iwasaki11111@gmail.com045-442-6475

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026